Siemens Healthineers has launched Syngo.CT Coronary Cockpit, a new software that integrates with the company’s dual-source and photon-counting CT scanners to evaluate patients with suspected coronary artery disease (CAD).
Coronary Cockpit uses AI algorithms to evaluate coronary CT angiography (CCTA) images.
By providing automated segmentation, labelling and visualisation of a patient’s coronary plaque buildup (atherosclerosis), Healthineers said the software will help clinicians to decide on the most appropriate treatment plans for individual patients ahead of percutaneous coronary intervention (PCI).
Healthineers unveiled the software during the 2025 Radiological Society of North America (RSNA) annual meeting, taking place between 30 November and 4 December in Chicago. Cockpit is currently pending US Food and Drug Administration (FDA) clearance. Once FDA-cleared, the software will be available through Healthineers’ Syngo.via2 platform.
By assisting clinicians in making pre-procedural decisions, such as lesion preparation, stent length, and landing-zone selection, Cockpit is expected to improve diagnostic and treatment pathways and reduce unnecessary cath lab referrals.
Siemens Healthineers's computed tomography head Philipp Fischer commented: “With Syngo.CT Coronary Cockpit, we combine our expertise in CT imaging and interventional therapy to help people with coronary artery disease live longer, healthier lives.
“This joint approach paves the way for a future where CT not only diagnoses but actively guides treatment decisions.”
Elsewhere at this year’s RSNA meeting, GE HealthCare launched Genesis Radiology Workspace, a new cloud-native radiology management system that aims to advance diagnostic workflows and optimise collaboration between radiologists.
In addition, Philips introduced BlueSeal Horizon at the event. The system comprises a helium-free 3.0T magnetic resonance imaging (MRI) platform that aims to remove the requirement for helium refills and vent pipes – a development expected to reduce installation complexity and overall lifecycle risk.
The rise of CCTA and AI in the medtech industry
CCTA is increasingly used in global clinical guidelines as a first-line tool for the diagnosis and planning in CAD procedures. The condition affects around 18 million adults in the US. Research indicates that the application of CCTA can more than halve referrals for diagnostic angiography, reduce costs, and shorten patient hospital stays.
Meanwhile, AI’s adoption across healthcare is continuing to rapidly advance, with GlobalData analysis forecasting that the technology’s application in the space will reach a $19bn valuation by 2027.
AI is proving to be especially significant in medical imaging. In August, HeartFlow completed a $364m initial public offering (IPO). As with Healthineers’ new software, HealthFlow’s lead product, HeartFlow Plaque, is used to quantify plaque buildup on the basis of CCTA images.
According to market observers, as one of the year’s biggest IPOs in the medical device space, HeartFlow’s success amply reflects the medtech industry’s embrace of the technology.
Healthineers recently announced EBIT of ‘just under’ €3.9bn in its fiscal year 2025 (FY25). Looking to 2026, the company said it expects revenue growth of 5%-6% versus FY25. Despite the company’s positive performance, in November, Siemens announced plans to ‘deconsolidate’ the Healthineers business, with further details of the separation expected in Q2 2026.
